Active — Not RecruitingNot Applicable

Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

South Korea2,845 participantsStarted 2022-06-20

Plain-language summary

The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate variables that affect treatment effectiveness.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. men and women over the age of 19
✓. Patients who signed a written consent form to participate in the study
✓. Patients who are eligible for Olostar tablet prescription according to domestic permission

Exclusion criteria

✕. A person who falls under "2. Do not administer to the following patients" among the precautions for use in the user manual
✕. Patients in hospital (hospitals only; nursing care facilities can be recruited)
✕. A person who has been administered the study target drug or is being administered at the time of recruitment within 6 months based on the date of the study contract

What they're measuring

absolute change and rate of change in low-density lipoprotein cholesterol (LDL-C)

Timeframe: 24 weeks

absolute change and rate of change in systolic and diastolic blood pressure

Timeframe: 24 weeks

Trial details

NCT IDNCT05411887

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-03-31

View on ClinicalTrials.gov More Hyperlipidemias trials